Cargando…
Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study
BACKGROUND: PATRO Children is an ongoing observational, longitudinal, non-interventional, global post-marketing surveillance study, which is investigating the long-term safety and effectiveness of Omnitrope®, a somatropin biosimilar to Genotropin®, in children with growth disturbances. The primary e...
Autores principales: | Iughetti, Lorenzo, Tornese, Gianluca, Street, Maria Elisabeth, Napoli, Flavia, Giavoli, Claudia, Antoniazzi, Franco, Stagi, Stefano, Luongo, Caterina, Azzolini, Sara, Ragusa, Letizia, Bona, Gianni, Zecchino, Clara, Aversa, Tommaso, Persani, Luca, Guazzarotti, Laura, Zecchi, Emiliano, Pietropoli, Alberto, Zucchini, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096288/ https://www.ncbi.nlm.nih.gov/pubmed/27809913 http://dx.doi.org/10.1186/s13052-016-0302-3 |
Ejemplares similares
-
Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(®)): data from the PATRO Adults study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2020) -
Safety and effectiveness of Omnitrope(®) (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data
por: Backeljauw, Philippe, et al.
Publicado: (2022) -
Long-term safety and efficacy of Omnitrope(®) in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study
por: Ferone, D., et al.
Publicado: (2017) -
No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019) -
SAT-437 The Patro Adults Study of Omnitrope® for the Treatment of Adult Patients with Growth Hormone Deficiency: Latest Safety Outcomes Including Diabetes Risk
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019)